Zobrazeno 81 - 90
of 140
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Herbert J. Zeh, Yong Chen, Melissa E. Hogg, Yan Jun, David L. Bartlett, Mazen S. Zenati, Jennifer Steve, Stacy J. Kowalsky, Amer H. Zureikat, Stephanie Novak
Publikováno v:
Annals of surgery. 264(3)
To evaluate and quantify surgical skill by grading surgical performance of the pancreaticojejunostomy from robotic pancreaticoduodenectomies (RPDs). We hypothesized that video grading of surgical performance would contribute to estimating risk of pos
Autor:
Mashaal, Dhir, Mazen S, Zenati, James C, Padussis, Heather L, Jones, Samantha, Perkins, Amber K, Clifford, Jennifer, Steve, Melissa E, Hogg, Haroon A, Choudry, Matthew P, Holtzman, Herbert J, Zeh, James F, Pingpank, David L, Bartlett, Amer H, Zureikat
Publikováno v:
Journal of surgical oncology. 114(3)
Hepatic artery infusion (HAI) chemotherapy can be combined with systemic chemotherapy for the treatment of isolated unresectable colorectal liver metastases (IU-CRLM) and intrahepatic cholangiocarcinoma (U-ICC). However, HAI pump placement requires a
Autor:
Herbert J. Zeh, Mazen S. Zenati, Nathan Bahary, Matthew J. Weiss, Jennifer Steve, G. Paul Wright, Amer H. Zuriekat, Katherine E. Poruk, Melissa E. Hogg, Christopher L. Wolfgang
Publikováno v:
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 20(11)
Patients with metastatic pancreatic adenocarcinoma have traditionally been offered palliative chemotherapy alone, and the role of surgery in these patients remains unknown. A bi-institutional retrospective review was performed for patients with metas
Autor:
Jennifer Steve, Amer H. Zureikat, Sharon Winters, Mazen S. Zenati, Jonathan C. King, David L. Bartlett, Melissa Hogg, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 23(13)
Morbidity and mortality of pancreatectomy has improved and chemotherapeutic options for pancreatic cancer (PC) are growing, yet there is reluctance to treat octogenarians. This study examined the reasons for failure to treat and analyzes outcomes in
Autor:
Robert Y. Rhee, Rolando I. Celis, Jae-Sung Cho, Sun C. Park, Michel S. Makaroun, Mazen S. Zenati, Ankur J. Shukla, Rabih A. Chaer
Publikováno v:
Journal of Vascular Surgery. 56(1):74-80
Objective To review the evolution of traumatic thoracic aortic injury (TTAI) treatment at a single institution. Methods Retrospective analysis of all patients included in an institutional trauma registry and vascular surgery database who underwent tr
Autor:
Anne Germain, Jason L. Sperry, Andrew B. Peitzman, Mazen S. Zenati, Amy S. Clontz, Dederia H. Nicholas, Louis H. Alarcon, Eileen Roach
Publikováno v:
Journal of Trauma and Acute Care Surgery. 72:629-637
Posttraumatic stress disorder (PTSD) is associated with significant morbidity following injury. The incidence and risk factors for PTSD are not well described in the civilian trauma population. We proposed to screen all trauma patients in the outpati
Autor:
Amir A. Borhani, Jennifer Steve, Amer H. Zureikat, H.J. Zeh, Patrick R. Varley, Mazen S. Zenati, Melissa E. Hogg, A. Klobuka, J. Tobler
Publikováno v:
HPB. 19:S42-S43
Autor:
Melissa E. Hogg, Jae P. Jung, Mashaal Dhir, H.J. Zeh, Mazen S. Zenati, Amer H. Zureikat, Stephanie Novak
Publikováno v:
HPB. 19:S10-S11
Autor:
Alain Corcos, Andrew B. Peitzman, Jason L. Sperry, Gary T. Marshall, Arshad M. Bachelani, Joshua T. Bautz, Mazen S. Zenati, Timothy R. Billiar
Publikováno v:
Surgery. 150:836-843
Platelet transfusion is utilized increasingly for traumatic brain injury (TBI) for the reversal of aspirin (ASA) therapy. Assessment of platelet inhibition and reversal by platelet transfusion after TBI has not been adequately characterized.A retrosp
Autor:
James M. Rossetti, John Lister, Mazen S. Zenati, Haifaa Abdulhaq, Entezam Sahovic, Folefac Atem, Bushra Haq, Joan M. Latsko, Richard K. Shadduck, Rubens Costa
Publikováno v:
Cancer. 117:2690-2696
BACKGROUND: Hypomethylating drugs are useful in the management of myelodysplastic syndrome (MDS). Two of these drugs, azacitidine and decitabine, have received FDA approval for the treatment of MDS and chronic myelomonocytic leukemia (CMML). However,